From the latest vaccination evidence, recommendations, and protocols . . . to new vaccine development and the use of vaccines in reducing disease, Plotkin’s Vaccines, 8th Edition, covers every aspect of vaccination. Now completely revised and updated from cover to cover, this award-winning text continues to provide reliable information from global authorities, offering a complete understanding of each disease, as well as the latest knowledge of both existing vaccines and those currently in research and development. Described by Bill Gates as "an indispensable guide to the enhancement of the well-being of our world," Plotkin’s Vaccines is a must-have reference for current, authoritative information in this fast-moving field.
Contains all-new chapters on COVID-19, vaccine hesitancy, and non-specific effects of vaccines, as well as significantly revised content on new vaccine technologies such as mRNA vaccines, emerging vaccines, and technologies to improve immunization.
Presents exciting new data on evolution of adjuvants across the centuries, dengue vaccines, human papillomavirus vaccines, respiratory syncytial virus vaccines, tuberculosis vaccines, and zoster vaccines.
Provides up-to-date, authoritative information on vaccine production, available preparations, efficacy and safety, and recommendations for vaccine use, with rationales and data on the impact of vaccination programs on morbidity and mortality.
Provides complete coverage of each disease, including clinical characteristics, microbiology, pathogenesis, diagnosis, and treatment, as well as epidemiology and public health and regulatory issues.
Keeps you up to date with information on each vaccine, including its stability, immunogenicity, efficacy, duration of immunity, adverse events, indications, contraindications, precautions, administration with other vaccines, and disease-control strategies.
Covers vaccine-preventable diseases, vaccine science, and licensed vaccine products, as well as product technologies and global regulatory and public health issues.
Analyzes the cost-benefit and cost-effectiveness of different vaccine options.
Helps you clearly visualize concepts and objective data through an abundance of tables and figures.
Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.
1. Cover image - p. Cover 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iii 5. Dedication - p. iii 6. Contributors - p. iii 7. Foreword - p. iii 8. Preface to the First Edition - p. iii 9. Preface to the Eighth Edition - p. iii 10. Acknowledgments - p. iii 11. Contents - p. iii 12. List of Illustrations - p. iii 13. List of Tables - p. iii 14. Chapter 1: A Short History of Vaccination - p. iii 15. Chapter 2: Vaccine Immunology - p. iii 16. Chapter 3: Non-specific Effects of Vaccines - p. iii 17. Chapter 4: Correlates of Protection - p. iii 18. Chapter 5: The Vaccine Industry - p. iii 19. Chapter 6: Vaccine Manufacturing - p. iii 20. Chapter 7: Evolution of Adjuvants Across the Centuries - p. iii 21. Chapter 8: Vaccine Additives and Manufacturing Residuals in Vaccines Licensed in the United States - p. iii 22. Chapter 9: Passive Immunization - p. iii 23. Chapter 10: General Immunization Practices - p. iii 24. Chapter 11: Human Adenovirus Vaccines - p. iii 25. Chapter 12: Anthrax Vaccines - p. iii 26. Chapter 13: Biodefense Vaccines, Vaccines for Emerging Infectious Diseases, and Coalition for Epidemic Preparedness Innovations (CEPI) - p. iii 27. Chapter 14: Cancer Vaccines - p. iii 28. Chapter 15: Cholera Vaccines - p. iii 29. Chapter 16: Combination Vaccines - p. iii 30. Chapter 17: Coronavirus Vaccines - p. iii 31. Chapter 18: Cytomegalovirus Vaccines - p. iii 32. Chapter 19: Dengue Vaccines - p. iii 33. Chapter 20: Vaccines Against Diarrhea Caused by Noncholera Bacteria - p. iii 34. Chapter 21: Diphtheria Toxoid - p. iii 35. Chapter 22: Ebola Vaccines - p. iii 36. Chapter 23: Nonpolio Enteroviruses - p. iii 37. Chapter 24: Epstein–Barr Virus Vaccines - p. iii 38. Chapter 25: Haemophilus influenzae Type b Vaccines - p. iii 39. Chapter 26: Hepatitis A Vaccines - p. iii 40. Chapter 27: Hepatitis B Vaccines - p. iii 41. Chapter 28: Hepatitis C Vaccines - p. iii 42. Chapter 29: Hepatitis E Vaccines - p. iii 43. Chapter 30: Herpes Simplex Virus Vaccines - p. iii 44. Chapter 31: Human Immunodeficiency Virus Vaccines - p. iii 45. Chapter 32: Human Papillomavirus Vaccines - p. iii 46. Chapter 33: Inactivated and Recombinant Influenza Vaccines - p. iii 47. Chapter 34: Influenza Vaccine—Live - p. iii 48. Chapter 35: Japanese Encephalitis Vaccines - p. iii 49. Chapter 36: Lyme Disease Vaccines—The Journey Continues - p. iii 50. Chapter 37: Malaria Vaccines - p. iii 51. Chapter 38: Online Supplements - p. iii 52. Chapter 39: Measles Vaccines - p. iii 53. Chapter 40: Meningococcal Capsular Group A, C, W, and Y Conjugate Vaccines - p. iii 54. Chapter 41: Meningococcal Vaccines Directed at Capsular Group B - p. iii 55. Chapter 42: Mumps Vaccines - p. iii 56. Chapter 43: Noninfectious Disease Vaccines - p. iii 57. Chapter 44: Norovirus - p. iii 58. Chapter 45: Parasitic Disease Vaccines - p. iii 59. Chapter 46: Pertussis Vaccines - p. iii 60. Chapter 47: Plague Vaccines - p. iii 61. Chapter 48: Pneumococcal Conjugate Vaccine and Pneumococcal Common Protein Vaccines - p. iii 62. Chapter 49: Pneumococcal Polysaccharide Vaccines - p. iii 63. Chapter 50: Poliovirus Vaccine—Inactivated - p. iii 64. Chapter 51: Poliovirus Vaccine–Live - p. iii 65. Chapter 52: Lyssaviruses and Rabies Vaccines - p. iii 66. Chapter 53: Respiratory Syncytial Virus Vaccines and Monoclonal Antibodies - p. iii 67. Chapter 54: Rotavirus Vaccines - p. iii 68. Chapter 55: Rubella Vaccines - p. iii 69. Chapter 56: Smallpox and Vaccinia - p. iii 70. Chapter 57: Staphylococcus aureus Vaccines - p. iii 71. Chapter 58: Streptococcus Group A Vaccines - p. iii 72. Chapter 59: Streptococcus Group B Vaccines - p. iii 73. Chapter 60: Tetanus Toxoid - p. iii 74. Chapter 61: Tickborne Encephalitis Vaccines - p. iii 75. Chapter 62: Tuberculosis Vaccines - p. iii 76. Chapter 63: Typhoid Fever Vaccines - p. iii 77. Chapter 64: Varicella Vaccines - p. iii 78. Chapter 65: Yellow Fever Vaccine - p. iii 79. Chapter 66: Zika Virus Vaccines - p. iii 80. Chapter 67: Zoster Vaccines - p. iii 81. Chapter 68: Technologies for Making New Vaccines - p. iii 82. Chapter 69: Genetic-Based Vaccine Vectors - p. iii 83. Chapter 70: Technologies to Improve Immunization - p. iii 84. Chapter 71: Vaccination of Immunocompromised Hosts - p. iii 85. Chapter 72: Vaccines for International Travel - p. iii 86. Chapter 73: Vaccines for Healthcare Personnel - p. iii 87. Chapter 74: Vaccination of Pregnant Women - p. iii 88. Chapter 75: Immunization in the United States - p. iii 89. Chapter 76: Immunization in Europe - p. iii 90. Chapter 77: Immunization and Vaccine-Preventable Diseases in the Asia-Pacific Region - p. iii 91. Chapter 78: Immunization in Low- and Middle-Income Countries - p. iii 92. Chapter 79: Community Protection - p. iii 93. Chapter 80: Economic Analyses of Vaccine Policies - p. iii 94. Chapter 81: Regulation and Testing of Vaccines in the US - p. iii 95. Chapter 82: Regulation of Vaccines in Europe - p. iii 96. Chapter 83: Regulation of Vaccines in Low- and Middle-Income Countries - p. iii 97. Chapter 84: Vaccine Safety - p. iii 98. Chapter 85: Vaccine Hesitancy and Behavioral Factors Associated With Vaccine Uptake - p. iii 99. Chapter 86: Legal Issues - p. iii 100. Chapter 87: Ethics - p. iii 101. Chapter 88: Vaccines to Prevent Mpox - p. iii 102. Websites and Applications for Mobile Devices With Information About Immunization - p. iii 103. Index - p. iii
From the latest vaccination evidence, recommendations, and protocols . . . to new vaccine development and the use of vaccines in reducing disease, Plotkin’s Vaccines, 8th Edition, covers every aspect of vaccination. Now completely revised and updated from cover to cover, this award-winning text continues to provide reliable information from global authorities, offering a complete understanding of each disease, as well as the latest knowledge of both existing vaccines and those currently in research and development. Described by Bill Gates as "an indispensable guide to the enhancement of the well-being of our world," Plotkin’s Vaccines is a must-have reference for current, authoritative information in this fast-moving field.
Contains all-new chapters on COVID-19, vaccine hesitancy, and non-specific effects of vaccines, as well as significantly revised content on new vaccine technologies such as mRNA vaccines, emerging vaccines, and technologies to improve immunization.
Presents exciting new data on evolution of adjuvants across the centuries, dengue vaccines, human papillomavirus vaccines, respiratory syncytial virus vaccines, tuberculosis vaccines, and zoster vaccines.
Provides up-to-date, authoritative information on vaccine production, available preparations, efficacy and safety, and recommendations for vaccine use, with rationales and data on the impact of vaccination programs on morbidity and mortality.
Provides complete coverage of each disease, including clinical characteristics, microbiology, pathogenesis, diagnosis, and treatment, as well as epidemiology and public health and regulatory issues.
Keeps you up to date with information on each vaccine, including its stability, immunogenicity, efficacy, duration of immunity, adverse events, indications, contraindications, precautions, administration with other vaccines, and disease-control strategies.
Covers vaccine-preventable diseases, vaccine science, and licensed vaccine products, as well as product technologies and global regulatory and public health issues.
Analyzes the cost-benefit and cost-effectiveness of different vaccine options.
Helps you clearly visualize concepts and objective data through an abundance of tables and figures.
Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.
1. Cover image - p. Cover 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iii 5. Dedication - p. iii 6. Contributors - p. iii 7. Foreword - p. iii 8. Preface to the First Edition - p. iii 9. Preface to the Eighth Edition - p. iii 10. Acknowledgments - p. iii 11. Contents - p. iii 12. List of Illustrations - p. iii 13. List of Tables - p. iii 14. Chapter 1: A Short History of Vaccination - p. iii 15. Chapter 2: Vaccine Immunology - p. iii 16. Chapter 3: Non-specific Effects of Vaccines - p. iii 17. Chapter 4: Correlates of Protection - p. iii 18. Chapter 5: The Vaccine Industry - p. iii 19. Chapter 6: Vaccine Manufacturing - p. iii 20. Chapter 7: Evolution of Adjuvants Across the Centuries - p. iii 21. Chapter 8: Vaccine Additives and Manufacturing Residuals in Vaccines Licensed in the United States - p. iii 22. Chapter 9: Passive Immunization - p. iii 23. Chapter 10: General Immunization Practices - p. iii 24. Chapter 11: Human Adenovirus Vaccines - p. iii 25. Chapter 12: Anthrax Vaccines - p. iii 26. Chapter 13: Biodefense Vaccines, Vaccines for Emerging Infectious Diseases, and Coalition for Epidemic Preparedness Innovations (CEPI) - p. iii 27. Chapter 14: Cancer Vaccines - p. iii 28. Chapter 15: Cholera Vaccines - p. iii 29. Chapter 16: Combination Vaccines - p. iii 30. Chapter 17: Coronavirus Vaccines - p. iii 31. Chapter 18: Cytomegalovirus Vaccines - p. iii 32. Chapter 19: Dengue Vaccines - p. iii 33. Chapter 20: Vaccines Against Diarrhea Caused by Noncholera Bacteria - p. iii 34. Chapter 21: Diphtheria Toxoid - p. iii 35. Chapter 22: Ebola Vaccines - p. iii 36. Chapter 23: Nonpolio Enteroviruses - p. iii 37. Chapter 24: Epstein–Barr Virus Vaccines - p. iii 38. Chapter 25: Haemophilus influenzae Type b Vaccines - p. iii 39. Chapter 26: Hepatitis A Vaccines - p. iii 40. Chapter 27: Hepatitis B Vaccines - p. iii 41. Chapter 28: Hepatitis C Vaccines - p. iii 42. Chapter 29: Hepatitis E Vaccines - p. iii 43. Chapter 30: Herpes Simplex Virus Vaccines - p. iii 44. Chapter 31: Human Immunodeficiency Virus Vaccines - p. iii 45. Chapter 32: Human Papillomavirus Vaccines - p. iii 46. Chapter 33: Inactivated and Recombinant Influenza Vaccines - p. iii 47. Chapter 34: Influenza Vaccine—Live - p. iii 48. Chapter 35: Japanese Encephalitis Vaccines - p. iii 49. Chapter 36: Lyme Disease Vaccines—The Journey Continues - p. iii 50. Chapter 37: Malaria Vaccines - p. iii 51. Chapter 38: Online Supplements - p. iii 52. Chapter 39: Measles Vaccines - p. iii 53. Chapter 40: Meningococcal Capsular Group A, C, W, and Y Conjugate Vaccines - p. iii 54. Chapter 41: Meningococcal Vaccines Directed at Capsular Group B - p. iii 55. Chapter 42: Mumps Vaccines - p. iii 56. Chapter 43: Noninfectious Disease Vaccines - p. iii 57. Chapter 44: Norovirus - p. iii 58. Chapter 45: Parasitic Disease Vaccines - p. iii 59. Chapter 46: Pertussis Vaccines - p. iii 60. Chapter 47: Plague Vaccines - p. iii 61. Chapter 48: Pneumococcal Conjugate Vaccine and Pneumococcal Common Protein Vaccines - p. iii 62. Chapter 49: Pneumococcal Polysaccharide Vaccines - p. iii 63. Chapter 50: Poliovirus Vaccine—Inactivated - p. iii 64. Chapter 51: Poliovirus Vaccine–Live - p. iii 65. Chapter 52: Lyssaviruses and Rabies Vaccines - p. iii 66. Chapter 53: Respiratory Syncytial Virus Vaccines and Monoclonal Antibodies - p. iii 67. Chapter 54: Rotavirus Vaccines - p. iii 68. Chapter 55: Rubella Vaccines - p. iii 69. Chapter 56: Smallpox and Vaccinia - p. iii 70. Chapter 57: Staphylococcus aureus Vaccines - p. iii 71. Chapter 58: Streptococcus Group A Vaccines - p. iii 72. Chapter 59: Streptococcus Group B Vaccines - p. iii 73. Chapter 60: Tetanus Toxoid - p. iii 74. Chapter 61: Tickborne Encephalitis Vaccines - p. iii 75. Chapter 62: Tuberculosis Vaccines - p. iii 76. Chapter 63: Typhoid Fever Vaccines - p. iii 77. Chapter 64: Varicella Vaccines - p. iii 78. Chapter 65: Yellow Fever Vaccine - p. iii 79. Chapter 66: Zika Virus Vaccines - p. iii 80. Chapter 67: Zoster Vaccines - p. iii 81. Chapter 68: Technologies for Making New Vaccines - p. iii 82. Chapter 69: Genetic-Based Vaccine Vectors - p. iii 83. Chapter 70: Technologies to Improve Immunization - p. iii 84. Chapter 71: Vaccination of Immunocompromised Hosts - p. iii 85. Chapter 72: Vaccines for International Travel - p. iii 86. Chapter 73: Vaccines for Healthcare Personnel - p. iii 87. Chapter 74: Vaccination of Pregnant Women - p. iii 88. Chapter 75: Immunization in the United States - p. iii 89. Chapter 76: Immunization in Europe - p. iii 90. Chapter 77: Immunization and Vaccine-Preventable Diseases in the Asia-Pacific Region - p. iii 91. Chapter 78: Immunization in Low- and Middle-Income Countries - p. iii 92. Chapter 79: Community Protection - p. iii 93. Chapter 80: Economic Analyses of Vaccine Policies - p. iii 94. Chapter 81: Regulation and Testing of Vaccines in the US - p. iii 95. Chapter 82: Regulation of Vaccines in Europe - p. iii 96. Chapter 83: Regulation of Vaccines in Low- and Middle-Income Countries - p. iii 97. Chapter 84: Vaccine Safety - p. iii 98. Chapter 85: Vaccine Hesitancy and Behavioral Factors Associated With Vaccine Uptake - p. iii 99. Chapter 86: Legal Issues - p. iii 100. Chapter 87: Ethics - p. iii 101. Chapter 88: Vaccines to Prevent Mpox - p. iii 102. Websites and Applications for Mobile Devices With Information About Immunization - p. iii 103. Index - p. iii
